Daiichi Sankyo, AZ get FDA’s BLA priority review for Trastuzumab Deruxtecan for Treatment of Patients with HER2 Positive Metastatic Breast Cancer

October 17, 2019 Off By BusinessWire

TOKYO & MUNICH & BASKING RIDGE, N.J.–(BUSINESS WIRE)–#BreastCancer–Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for [fam-] trastuzumab deruxtecan (DS-8201) and granted Priority Review.

The Prescription Drug User Fee Act (PDUFA) date for [fam-] trastuzumab deruxtecan, an investigational HER2 targeting antibody drug conjugate (ADC), for the treatment of patients with HER2 positive metastatic breast cancer is set for the first quarter of fiscal year 2020.

“We are pleased that the FDA has accepted the application and granted Priority Review as we believe [fam-] trastuzumab deruxtecan has the potential to redefine the treatment of patients with HER2 positive metastatic breast cancer,” said Antoine Yver, MD, MSc, Executive Vice President and Global Head, Oncology Research and Development, Daiichi Sankyo. “Following the recent regulatory submission in Japan, we look forward to working closely with regulatory authorities to bring [fam-] trastuzumab deruxtecan to patients in the U.S. and Japan as soon as possible.”

“[Fam-] trastuzumab deruxtecan has the potential to transform the treatment landscape for patients with HER2 positive metastatic breast cancer who have limited treatment options,” said José Baselga, MD, PhD, Executive Vice President, Research & Development Oncology, AstraZeneca. “The priority review draws on the strength and consistency of results seen in phase 1 and phase 2 trials and is an important step on the journey to deliver this potential new medicine to patients.”